Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Myriad Genetics, Inc. (MYGN) had Receiveable Turnover of 6.59 for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$753.20M |
|
$-263.30M |
|
$236.20M |
|
$517.00M |
|
$1.01B |
|
$-257.40M |
|
$-4.80M |
|
$-262.20M |
|
$-262.20M |
|
$-263.30M |
|
$-263.30M |
|
$-263.30M |
|
$-263.30M |
|
$-257.40M |
|
$-195.50M |
|
82.80M |
|
82.80M |
|
$-3.18 |
|
$-3.18 |
|
| Balance Sheet Financials | |
$313.60M |
|
$119.00M |
|
$832.90M |
|
$1.15B |
|
$155.90M |
|
$38.50M |
|
$207.40M |
|
$363.30M |
|
$783.20M |
|
$146.30M |
|
$783.20M |
|
89.90M |
|
| Cash Flow Statement Financials | |
$-110.90M |
|
$31.90M |
|
$152.90M |
|
$66.40M |
|
$140.90M |
|
$74.50M |
|
$40.70M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.01 |
|
-- |
|
-- |
|
0.05 |
|
0.05 |
|
68.64% |
|
-34.17% |
|
-34.17% |
|
-25.96% |
|
-34.81% |
|
-34.96% |
|
$-174.10M |
|
-- |
|
-- |
|
-- |
|
0.66 |
|
10.74 |
|
|
Receiveable Turnover |
6.59 |
55.39 |
|
-33.62% |
|
-179.97% |
|
-22.97% |
|
-32.04% |
|
$8.71 |
|
$-2.10 |
|
$-1.34 |
|